07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

RT001: Preliminary Phase I/II data

Preliminary data from a double-blind U.S. Phase I/II trial in 18 patients with Friedreich’s ataxia showed that once-daily 1.8 g oral RT001 and twice-daily 4.5 g oral RT001 given for 28 days were well tolerated....
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

RT001: Phase I/II started

Retrotope began a double-blind, dose-escalation, U.S. Phase I/II trial to compare oral RT001 vs. encapsulated non-deuterated linoleic acid ethyl ester for 28 days in 18 ambulatory patients. Patients will receive once-daily 1.8 g RT001 or...
07:00 , Jun 12, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Approach

Approach Summary Licensing status Publication and contact information Disease models Heart-on-a-chip model for cardiomyopathy caused by Barth syndrome A heart-on-a-chip model for Barth syndrome-associated cardiomyopathy could help identify new...
07:00 , Oct 29, 2012 |  BioCentury  |  Regulation

Familial competition

If FDA follows its advisory panel's recommendation, Aegerion Pharmaceuticals Inc. and Sanofi's Genzyme Corp. unit could each be launching new drugs to treat the ultra-Orphan disease homozygous familial hypercholesterolemia early next year. But neither the...
08:00 , Feb 17, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Alzheimer's disease (AD) Protein kinase Ce (PKCE) Studies in cell culture and in mice suggest that...
07:00 , Oct 29, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Pain 9-Hydroxyoctadecadienoic acid...
08:00 , Mar 5, 2001 |  BC Week In Review  |  Company News

AMBI other research news

AMBI said that in cell culture, its product combining chromium picolinate ( CP) with alpha lipoic acid (APA) significantly increased glucose uptake by insulin-stimulated muscle cells and that its product combining CP with conjugated ...
08:00 , Jan 17, 2000 |  BC Week In Review  |  Clinical News

Epogam and Efamast regulatory update

SOH said that the U.K.'s Committee on Safety of Medicines will review the company's Epogam and Efamast, which restore levels of gamma linoleic acid metabolites to treat atopic eczema and breast pain, respectively. The...
08:00 , Nov 23, 1998 |  BC Week In Review  |  Clinical News

AVI preclinical data

AVII reported that its CytoPorter technology, combined with glycerol and linoleic acid, was able to transport peptide compounds across the skin of hairless mice into the bloodstream. The company said the process could be...
08:00 , Jan 26, 1998 |  BC Week In Review  |  Clinical News

Scotia Holdings Group regulatory update

SOH's Scotia Pharmaceuticals Ltd. subsidiary received U.K. approval to market once per day oral emulsion formulations of Epogam to treat atopic eczema and Efamast to treat breast pain, and a topical cream formulation of Efalith,...